Abstract
Introduction
This analysis examines the historical and forecast performance for BMS in the
prescription pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Key reasons to purchase this research
- Benchmark Bristol-Myers Squibb' s performance against key rivals in the
ethical pharmaceutical sector
- Assess how BMS is exploring the fast-growth oncology and immunology
disease markets to drive long-term sales in the face of blockbuster patent
expiry
- Investigate the strength of BMS' s pipeline, its product collaborations
with AstraZeneca and Pfizer and the recent acquisition of Medarex.
| 
View Cart
